Skip to main content
SpringerLink
Log in

The importance of genetic and nutritional factors in responses to vitamin D and its analogs in osteoporotic patients

  • Satellite Symposium on New Aspects in Therapy With Active Vitamin D Derivatives May 19, 1996 Amsterdam, The Netherlands
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

The effects of vitamin D and its analogs on fractures and bone mass have been clarified by clinical observations for more than 10 years. Reviewing the results of six clinical trials on osteoporotic fractures using activated vitamin D analogs, there appeared to be a negative correlation between basal levels of calcium intake and the incidence of vertebral fractures in the control groups. For example, when daily calcium intake was about 600 mg, there were approximately 800 vertebral fractures per 1000 persons a year in the controls. When daily calcium intake was above 1000 mg, the incidence was less than 400 fractures per 1000 persons a year. The incidence of fractures decreased by about half in the activated vitamin D-treated group compared with the control group, but the most marked preventive effects of activated vitamin D on fractures were obtained in clinical studies, with daily calcium intakes of 400–800 mg. The effects of vitamin D analogs on bone mass were reported in the clinical studies, but the results are not consistent. However, these studies suggest that the effects of both 1,25(OH)2D3 and l-alpha(OH)D3 on bone mass were dose dependent, and the doses were low in clinical studies in which good results were not obtained. Significant effects on bone mass were obtained when more than 0.6 μg of 1,25(OH)2D3, or more than 0.75 μg of l-alpha(OH)D3 was administered, with increase in the urinary calcium level being within the acceptable range. Reported data indicate that both nonactivated vitamin D and activated vitamin D reduce the serum parathyroid hormone level. However, activated vitamin D administration is more effective, and is able to reduce bone resorption in postmenopausal, osteoporotic patients with a vitamin D-sufficient status. Recent studies concerning the polymorphism of the vitamin D-receptor gene emphasize that sensitivity to active vitamin D varies between genotypes. In the bb type, sensitivity to active vitamin D is high, and calcium absorption efficiency in the intestine under low calcium conditions increases with increase in the serum 1,25(OH)2D level. A significant increase in lumbar bone mineral density was obtained after administration of activated vitamin D to osteoporotic patients of bb type. However, in the genotype with the B factor, sensitivity to active vitamin D was low, and the rate of increase of bone density was low. These data suggest that nutritional and genetic factors are critical when using active vitamin D and its analogs in the treatment of osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tsai KS, Heath H III, Kumar R, Riggs BL (1984) Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis. J Clin Invest 73:1668–1772

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Slovik DM, Adams JS, Nier RM, Holick MF, Potts JT Jr (1981) Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N Engl J Med 305:372–374

    Article  CAS  PubMed  Google Scholar 

  3. Alevizaki CC, Ikkos DG, Singhelakis P (1965) Progressive decrease of true intestinal calcium absorption with age in normal man. J Nucl Med 14:760–762

    Google Scholar 

  4. Gallagher JC, Riggs BL, Eisman J, Hamtra A, Arnaud SB, DeLuca HF (1979) Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium. J Clin Invest 64: 729–736

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Kanis JA (1994) Calcitriol, alfacalcidol and related analogues. In: Osteoporosis. Blackwell Science Ltd, Oxford, pp 212–213

    Google Scholar 

  6. Orimo H, Shiraki Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N (1994) Effects of lahydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370–376

    Article  CAS  PubMed  Google Scholar 

  7. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnoud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642

    Article  CAS  PubMed  Google Scholar 

  8. Tilyard MW, Spears GFS, Thompson J, Dorey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–362

    Article  CAS  PubMed  Google Scholar 

  9. Ooms ME, Roos JC, Bezemer PD, Van D Vijgh WJF, Bouter LM, Lips P (1995) Prevention of bone loss by vitamin D supplementation in elderly women: a randomized doubleblind trial. J Clin Endocrinol Metab 80:1052–1058

    CAS  PubMed  Google Scholar 

  10. Shiraki M, Ito H, Orimo H (1993) The ultra long-term treatment of senile osteoporosis with la-hydroxyvitamin D3. Bone Miner 20:223–234

    Article  CAS  PubMed  Google Scholar 

  11. Ott MS, Chesnut CH (1989) Calcitriol is not effective in post-menopausal osteoporosis. Ann Intern Med 110:267–274

    Article  CAS  PubMed  Google Scholar 

  12. Ott MS, Chesnut CH (1990) Tolerance of dose of calcitriol is associated with improved bone density in women with post-menopausal osteoporosis. J Bone Miner Res 5 (suppl 1):S449

    Google Scholar 

  13. Gallagher JC, Goldgar D (1990) Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. Ann Intern Med 113:649–655

    Article  CAS  PubMed  Google Scholar 

  14. Smith D, Nance W, Wong Kang K, Christian J, Johnston CJ (1973) Genetic factors in determining bone mass. J Clin Invest 52:2800–2808

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Pock NA, Eisman JA, Hooper JL, Yeates MG, Sambrook PN, Eberl S (1987) Genetic determinants of bone mass in adults: a twin study. J Clin Invest 80:706–710

    Article  Google Scholar 

  16. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA (1994) Prediction of bone density from vitamin D receptor allele. Nature 367:284–287

    Article  CAS  PubMed  Google Scholar 

  17. Morrison NA, Yeoman R, Kelly PJ, Eisman JA (1992) Contribution of transacting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc Natl Acad Sci USA 89:284–287

    Article  Google Scholar 

  18. Wiske PS, Epstein S, Bell NH, Queener SF, Edmondson J, Johnston CC Jr (1979) Increases in immunoreactive parathyroid hormone with aging. N Engl J Med 300:1419–1421

    Article  CAS  PubMed  Google Scholar 

  19. Orimo M, Shiraki M, Hayashi Y, Nakamura T (1987) Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with la-(OH)-vitamin D3. Bone Miner 3: 47–52

    CAS  PubMed  Google Scholar 

  20. Gallagher JC, Riggs BL (1989) The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 19:287–292

    Article  Google Scholar 

  21. Hayashi Y, Fujita T, Inoue T (1992) Decrease of vertebral fracture in osteoporotic patients by administration of lalpha(OH)D3. J Bone Miner Metab 10:184–188

    Article  Google Scholar 

  22. Tilyard MW, Spears GFS, Com B, Thomsen J, Dovey S (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357–362

    Article  CAS  PubMed  Google Scholar 

  23. Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH (1987) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84:401–408

    Article  Google Scholar 

  24. Tanaka N, Chen JT, Kato T, Hasumi K, Ogata E, Shiraki M (1995) Effect of lalpha-hydroxyvitamin D3 on postmenopausal osteoporosis was accompanied with increased calcitonin secretion. J Bone Miner Res 10(suppl 1):S354

    Google Scholar 

  25. Christiansen C, Christensen MS, Rodbro P, Hagen C, Transbol I (1981) Effect of 1,25-dihydroxyvitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. Eur J Clin Invest 11:305–309

    Article  CAS  PubMed  Google Scholar 

  26. Falch JA, Odegaard OR, Finnanger AM, Mattheson I (1987) Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand 221:199–204

    Article  CAS  PubMed  Google Scholar 

  27. Christiansen C, Christiansen MS, McNair P, Hagen C, Stocklund K, Transbol I (1980) Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 10:273–279

    Article  CAS  PubMed  Google Scholar 

  28. Bell NH (1995) Vitamin D metabolism, aging, and bone loss (editorial). J Clin Endocrinol Metab 80:1051

    CAS  PubMed  Google Scholar 

  29. Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y, Nishii Y (1994) A novel synthetic vitamin D analogue, 2β-(3-hydroxypropoxy)la-25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 54:142–149

    Article  CAS  PubMed  Google Scholar 

  30. Kurokawa K (1994) The kidney and calcium homeostasis. Kidney Int 45 (suppl 44):S97-S105

    Google Scholar 

  31. Peacock M (1995) Vitamin D receptor gene alleles and osteoporosis: a contrasting view (editorial). J Bone Miner Res 10: 1294–1297

    Article  CAS  PubMed  Google Scholar 

  32. Garnero P, Borel O, Sornay-Rendu E, Delmas P (1995) Vitamin D receptor gene polymorphisms do not predict bone turnover and bone mass in healthy premenopausal women. J Bone Miner Res 10:1283–1288

    Article  CAS  PubMed  Google Scholar 

  33. Yamagata Z, Miyamura T, Iijima S, Asaka A, Sasaki M, Kato J, Koizumi K (1994) Vitamin D receptor gene polymorphism and bone mineral density in healthy Japanese women. Lancet 344:1027

    Article  CAS  PubMed  Google Scholar 

  34. Krall EA, Parry P, Lichter JB, Dawson-Hughes B (1995) Vitamin D receptor alleles and rates of bone loss: influences of year since menopause and calcium intake. J Bone Miner Res 10:978–984

    Article  CAS  PubMed  Google Scholar 

  35. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S (1990) A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 328:878–883

    Article  Google Scholar 

  36. Dawson-Hughes B, Harris SS, Finneran S (1995) Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype. J Bone Miner Res 10:S162

    Google Scholar 

  37. Matsuyama T, Ishii S, Tokita A, Yabuta K, Yamamori S, Morrison NA, Eisman JA (1995) Vitamin D receptor genotypes and bone mineral density. Lancet 345:1238–1239

    Article  CAS  PubMed  Google Scholar 

  38. Shiraki M, Eguchi H, Aoki C (1995) Can allelic variations in vitamin D receptor gene predict bone density and serum osteocalcin level in Japanese women? Bone 16(suppl):84S

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Orthopedic Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, 807, Kitakyushu, Japan

    T. Nakamura

Authors
  1. T. Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, T. The importance of genetic and nutritional factors in responses to vitamin D and its analogs in osteoporotic patients. Calcif Tissue Int 60, 119–123 (1997). https://doi.org/10.1007/s002239900199

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002239900199

Key words

Search

Navigation